Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2020

01-12-2020 | Peritoneal Surface Malignancy

Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative

Authors: Adriana C. Gamboa, MD, MS, Rachel M. Lee, MD, MSPH, Michael K. Turgeon, MD, Mohammad Y. Zaidi, MD, MS, Charles W. Kimbrough, MD, Travis E. Grotz, MD, Jennifer Leiting, MD, MS, Keith Fournier, MD, Andrew J. Lee, MD, Sean P. Dineen, MD, Benjamin D. Powers, MD, MS, Jula Veerapong, MD, Joel M. Baumgartner, MD, MAS, Callisia N. Clarke, MD, Harveshp Mogal, MD, Sameer H. Patel, MD, Tiffany C. Lee, MD, Laura A. Lambert, MD, Ryan J. Hendrix, MD, Daniel E. Abbott, MD, Courtney Pokrzywa, MD, Mustafa Raoof, MD, Oliver S. Eng, MD, Fabian M. Johnston, MD, MHS, Jonathan Greer, MD, Jordan M. Cloyd, MD, Shishir K. Maithel, MD, Charles A. Staley, MD

Published in: Annals of Surgical Oncology | Issue 13/2020

Login to get access

Abstract

Background

Postoperative complications (POCs) are associated with worse oncologic outcomes in various cancer histologies. The impact of POCs on the survival of patients with appendiceal or colorectal cancer after cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is unknown.

Methods

The US HIPEC Collaborative (2000–2017) was reviewed for patients who underwent CCR0/1 CRS/HIPEC for appendiceal/colorectal cancer. The analysis was stratified by noninvasive appendiceal neoplasm versus invasive appendiceal/colorectal adenocarcinoma. The POCs were grouped into infectious, cardiopulmonary, thromboembolic, and intestinal dysmotility. The primary outcomes were overall survival (OS) and recurrence-free survival (RFS).

Results

Of the 1304 patients, 33% had noninvasive appendiceal neoplasm (n = 426), and 67% had invasive appendiceal/colorectal adenocarcinoma (n = 878). In the noninvasive appendiceal cohort, POCs were identified in 55% of the patients (n = 233). The 3-year OS and RFS did not differ between the patients who experienced a complication and those who did not (OS, 94% vs 94%, p = 0.26; RFS, 68% vs 60%, p = 0.15). In the invasive appendiceal/colorectal adenocarcinoma cohort, however, POCs (63%; n = 555) were associated with decreased 3-year OS (59% vs 74%; p < 0.001) and RFS (32% vs 42%; p < 0.001). Infectious POCs were the most common (35%; n = 196). In Multivariable analysis accounting for gender, peritoneal cancer index (PCI), and incomplete resection (CCR1), infectious POCs in particular were associated with decreased OS compared with no complication (hazard ratio [HR] 2.08; p < 0.01) or other types of complications (HR, 1.6; p < 0.01). Similarly, infectious POCs were independently associated with worse RFS (HR 1.61; p < 0.01).

Conclusion

Postoperative complications are associated with decreased OS and RFS after CRS/HIPEC for invasive histology, but not for an indolent disease such as noninvasive appendiceal neoplasm, and this association is largely driven by infectious complications. The exact mechanism is unknown, but may be immunologic. Efforts must target best practices and standardized prevention strategies to minimize infectious postoperative complications.
Literature
1.
go back to reference Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.CrossRef Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.CrossRef
2.
go back to reference Buvanendran A, Kroin JS, Berger RA, et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology. 2006;104:403–10.CrossRef Buvanendran A, Kroin JS, Berger RA, et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology. 2006;104:403–10.CrossRef
3.
go back to reference Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg. 2000;232:58–65.CrossRef Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg. 2000;232:58–65.CrossRef
4.
go back to reference Shen P, Stewart JHT, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale. Curr Probl Cancer. 2009; 33: 125–41.CrossRef Shen P, Stewart JHT, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale. Curr Probl Cancer. 2009; 33: 125–41.CrossRef
5.
go back to reference Sugarbaker PH. Gastric cancer: prevention and treatment of peritoneal metastases. J Cancer Metastasis Treat. 2018;4:7.CrossRef Sugarbaker PH. Gastric cancer: prevention and treatment of peritoneal metastases. J Cancer Metastasis Treat. 2018;4:7.CrossRef
6.
go back to reference Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2:109–16.CrossRef Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2:109–16.CrossRef
7.
go back to reference Laurent C, Sa Cunha A, Couderc P, Rullier E, Saric J. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90:1131–6.CrossRef Laurent C, Sa Cunha A, Couderc P, Rullier E, Saric J. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90:1131–6.CrossRef
8.
go back to reference Artinyan A, Orcutt ST, Anaya DA, Richardson P, Chen GJ, Berger DH. Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients. Ann Surg. 2015;261:497–505.CrossRef Artinyan A, Orcutt ST, Anaya DA, Richardson P, Chen GJ, Berger DH. Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients. Ann Surg. 2015;261:497–505.CrossRef
9.
go back to reference Rizk NP, Bach PB, Schrag D, et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004; 198: 42–50CrossRef Rizk NP, Bach PB, Schrag D, et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004; 198: 42–50CrossRef
10.
go back to reference Dorcaratto D, Mazzinari G, Fernandez M, et al. Impact of postoperative complications on survival and recurrence after resection of colorectal liver metastases: systematic review and meta-analysis. Ann Surg. 2019;270(6):1018–27.CrossRef Dorcaratto D, Mazzinari G, Fernandez M, et al. Impact of postoperative complications on survival and recurrence after resection of colorectal liver metastases: systematic review and meta-analysis. Ann Surg. 2019;270(6):1018–27.CrossRef
11.
go back to reference Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253:890–9.CrossRef Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253:890–9.CrossRef
12.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240: 205–13CrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240: 205–13CrossRef
13.
go back to reference Jafari MD, Halabi WJ, Stamos MJ, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 2014;149:170–5.CrossRef Jafari MD, Halabi WJ, Stamos MJ, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 2014;149:170–5.CrossRef
14.
go back to reference Gani F, Conca-Cheng AM, Nettles B, Ahuja N, Johnston FM. Trends in outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Res. 2019; 234: 240–8.CrossRef Gani F, Conca-Cheng AM, Nettles B, Ahuja N, Johnston FM. Trends in outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Res. 2019; 234: 240–8.CrossRef
15.
go back to reference Levine EA, Stewart JH 4th, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures [published correction appears in J Am Coll Surg. 2007 Oct;205(4):630]. J Am Coll Surg. 2007; 204: 943–53.CrossRef Levine EA, Stewart JH 4th, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures [published correction appears in J Am Coll Surg. 2007 Oct;205(4):630]. J Am Coll Surg. 2007; 204: 943–53.CrossRef
16.
go back to reference Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey J-N. Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110:107–14.CrossRef Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey J-N. Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110:107–14.CrossRef
17.
go back to reference Pachot A, Cazalis MA, Venet F, et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol Baltimore. 2008;180:6421–9. Pachot A, Cazalis MA, Venet F, et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol Baltimore. 2008;180:6421–9.
18.
go back to reference Restifo NP, Antony PA, Finkelstein SE, et al. Assumptions of the tumor “escape” hypothesis. Semin Cancer Biol. 2002;12:81–6.CrossRef Restifo NP, Antony PA, Finkelstein SE, et al. Assumptions of the tumor “escape” hypothesis. Semin Cancer Biol. 2002;12:81–6.CrossRef
19.
go back to reference Ben-Eliyahu S, Golan T. Harnessing the perioperative period to improve long-term cancer outcomes. JNCI: J Natl Cancer Inst. 2018;110:1137–8. Ben-Eliyahu S, Golan T. Harnessing the perioperative period to improve long-term cancer outcomes. JNCI: J Natl Cancer Inst. 2018;110:1137–8.
20.
go back to reference Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intraabdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575–83.CrossRef Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intraabdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575–83.CrossRef
21.
go back to reference Wiseman JT, Kimbrough C, Beal EW, et al. Predictors of anastomotic failure after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: does technique matter. Ann Surg Oncol. 2020;27(3):783–92.CrossRef Wiseman JT, Kimbrough C, Beal EW, et al. Predictors of anastomotic failure after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: does technique matter. Ann Surg Oncol. 2020;27(3):783–92.CrossRef
22.
go back to reference Raspe C, Flother L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2017;43:1013–27.CrossRef Raspe C, Flother L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2017;43:1013–27.CrossRef
Metadata
Title
Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative
Authors
Adriana C. Gamboa, MD, MS
Rachel M. Lee, MD, MSPH
Michael K. Turgeon, MD
Mohammad Y. Zaidi, MD, MS
Charles W. Kimbrough, MD
Travis E. Grotz, MD
Jennifer Leiting, MD, MS
Keith Fournier, MD
Andrew J. Lee, MD
Sean P. Dineen, MD
Benjamin D. Powers, MD, MS
Jula Veerapong, MD
Joel M. Baumgartner, MD, MAS
Callisia N. Clarke, MD
Harveshp Mogal, MD
Sameer H. Patel, MD
Tiffany C. Lee, MD
Laura A. Lambert, MD
Ryan J. Hendrix, MD
Daniel E. Abbott, MD
Courtney Pokrzywa, MD
Mustafa Raoof, MD
Oliver S. Eng, MD
Fabian M. Johnston, MD, MHS
Jonathan Greer, MD
Jordan M. Cloyd, MD
Shishir K. Maithel, MD
Charles A. Staley, MD
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08843-6

Other articles of this Issue 13/2020

Annals of Surgical Oncology 13/2020 Go to the issue